导管消融与抗心律失常药物对心房颤动患者生活质量的影响:CAPTAF随机临床试验
在瑞典4所和芬兰1所大学医院开展的随机临床试验,纳入155例30-70岁、心房颤动超过6个月且1种抗心律失常药或β受体阻滞剂治疗失败的患者,比较肺静脉隔离消融(n=79)与既往未试过的抗心律失常药(n=76)在12个月时生活质量(36项简表调查一般健康子量表)的变化。消融组一般健康评分从61.8升至73.9分,药物组从62.7升至65.4分,组间差异8.9分(95%CI 3.1-14.7;P=.003)。作者结论:尽管研究缺乏盲法,导管消融可能对生活质量有优势。
要点
- 心房颤动负荷消融组从24.9%降至5.5%,药物组从23.3%降至11.5%,差异-6.8%(95%CI -12.9%至-0.7%;P=.03)。
- 消融组最常见不良事件为尿源性脓毒症(5.1%),药物组为房性心动过速(3.9%)。
核心结论
- 在有症状且抗心律失常药物治疗后仍发作的心房颤动患者中,12个月时导管消融组生活质量改善大于抗心律失常药物组。
- 作者认为尽管研究缺乏盲法,导管消融可能对生活质量有优势。
研究设计与样本
- 随机临床试验,在瑞典4所大学医院和芬兰1所大学医院开展,纳入155例30-70岁、心房颤动超过6个月且1种抗心律失常药或β受体阻滞剂治疗失败的患者,随访4年。
- 研究日期为2008年7月至2017年9月;主要排除标准为射血分数<35%、左心房内径>60 mm、依赖心室起搏和既往消融。
- 干预为肺静脉隔离消融(n=79)或既往未试过的抗心律失常药(n=76)。
主要发现
- 155例随机患者平均年龄56.1岁,女性占22.6%,97%完成试验;消融组79例中75例接受消融,其中2例交叉至药物、14例接受重复消融;药物组76例中74例接受药物,其中8例交叉至消融、43例第一种药物使用失败。
- 一般健康评分消融组从61.8分升至73.9分,药物组从62.7分升至65.4分,组间差异8.9分(95%CI 3.1-14.7;P=.003)。
- 26个次要终点中分析了5个,2个为阴性、2个有统计学意义,中心房颤动负荷消融组从24.9%降至5.5%,药物组从23.3%降至11.5%,差异-6.8%(95%CI -12.9%至-0.7%;P=.03)。
- 健康调查子量表中7个有5个显著改善;消融组最常见不良事件为尿源性脓毒症(5.1%),药物组为房性心动过速(3.9%)。
关键数值与推荐
- 主要终点为36项简表调查一般健康子量表评分(范围0分最差至100分最佳),在基线和12个月时非盲法评估。
- 心房颤动负荷以植入式心脏监测器测得的发作时间百分比表示,从基线至12个月,节律分析排除前3个月。
临床怎么用
- 原文未据此给出推荐;作者结论为在有症状且抗心律失常药物治疗后仍发作的心房颤动患者中,12个月时导管消融组生活质量改善大于药物组,尽管研究缺乏盲法,导管消融可能对生活质量有优势。
局限性
- 研究缺乏盲法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Quality of life is not a standard primary outcome in ablation trials, even though symptoms drive the indication. OBJECTIVE: To assess quality of life with catheter ablation vs antiarrhythmic medication at 12 months in patients with atrial fibrillation. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial at 4 university hospitals in Sweden and 1 in Finland of 155 patients aged 30-70 years with more than 6 months of atrial fibrillation and treatment failure with 1 antiarrhythmic drug or β-blocker, with 4-year follow-up. Study dates were July 2008-September 2017. Major exclusions were ejection fraction <35%, left atrial diameter >60 mm, ventricular pacing dependency, and previous ablation. INTERVENTIONS: Pulmonary vein isolation ablation (n = 79) or previously untested antiarrhythmic drugs (n = 76). MAIN OUTCOMES AND MEASURES: Primary outcome was the General Health subscale score (Medical Outcomes Study 36-Item Short-Form Health Survey) at baseline and 12 months, assessed unblinded (range, 0 [worst] to 100 [best]). There were 26 secondary outcomes, including atrial fibrillation burden (% of time) from baseline to 12 months, measured by implantable cardiac monitors. The first 3 months were excluded from rhythm analysis. RESULTS: Among 155 randomized patients (mean age, 56.1 years; 22.6% women), 97% completed the trial. Of 79 patients randomized to receive ablation, 75 underwent ablation, including 2 who crossed over to medication and 14 who underwent repeated ablation procedures. Of 76 patients randomized to receive antiarrhythmic medication, 74 received it, including 8 who crossed over to ablation and 43 for whom the first drug used failed. General Health score increased from 61.8 to 73.9 points in the ablation group vs 62.7 to 65.4 points in the medication group (between-group difference, 8.9 points; 95% CI, 3.1-14.7; P = .003). Of 26 secondary end points, 5 were analyzed; 2 were null and 2 were statistically significant, including decrease in atrial fibrillation burden (from 24.9% to 5.5% in the ablation group vs 23.3% to 11.5% in the medication group; difference -6.8% [95% CI, -12.9% to -0.7%]; P = .03). Of the Health Survey subscales, 5 of 7 improved significantly. Most common adverse events were urosepsis (5.1%) in the ablation group and atrial tachycardia (3.9%) in the medication group. CONCLUSIONS AND RELEVANCE: Among patients with symptomatic atrial fibrillation despite use of antiarrhythmic medication, the improvement in quality of life at 12 months was greater for those treated with catheter ablation compared with antiarrhythmic medication. Although the study was limited by absence of blinding, catheter ablation may offer an advantage for quality of life. TRIAL REGISTRATION: clinicaltrialsregister.eu Identifier: 2008-001384-11.
引用
- Blomström-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients With Atrial Fibrillation: The CAPTAF Randomized Clinical Trial. JAMA. 2019. PMID: 30874754. doi:10.1001/jama.2019.0335
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。